Science’s COVID-19 reporting is supported by the Heising-Simons Foundation.
A confusing and unusually nasty fight broke out this week over the safety of a Russian COVID-19 vaccine known as Sputnik V after a Brazilian health agency declined on Monday to authorize its import because of quality and safety concerns. The stakes escalated yesterday when the Twitter account officially associated with the vaccine said “Sputnik V is undertaking a legal defamation proceeding” against Brazil’s regulators.
In an online press conference several hours later, the Brazilian Health Regulatory Agency (Anvisa) defended its decision, maintaining that documentation from some of the Russian facilities making Sputnik V shows that one of its two doses contains adenoviruses capable of replication, a potential danger to vaccine recipients. The vaccine uses two different adenoviruses, which cause the common cold, to deliver the gene for the spike protein of SARS-CoV-2, the virus that causes COVD-1
Stony Brook University students joining study of Moderna vaccine effectiveness newsday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsday.com Daily Mail and Mail on Sunday newspapers.
First, let’s get this straight. The term “hesitancy” would apply to your pasty-faced nephew, who plays video games 19 hours a day, who’s dragged to the beach one summer afternoon, and is reluctant to stick his toe in the water as he stands near the last little gasp of foam breaking on the sand.
Most of the people who aren’t taking the COVID vaccine aren’t hesitant at all. They’re determined to reject the shot.
Most of the people who don’t want the COVID vaccine are quite sure they want to forego genetic damage, blood clots, and death.
Santhera and ReveraGen Announce New 2.5-year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy
Pratteln, Switzerland, April 28, 2021 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma announce new clinical data of 2.5-year treatment outcome with vamorolone in patients with Duchenne muscular dystrophy (DMD). These Phase 2a long-term treatment data demonstrate
a maintenance of treatment effect, equivalent to a delay of about two years in decline for
time to stand (TTSTAND) velocity, and confirm safety and tolerability benefits of vamorolone over the 2.5-year follow up period.
Long-term treatment with vamorolone resulted in significantly fewer corticosteroid-associated adverse events than reported in other clinical trials with other steroids.
Moderna ramps up COVID-19 vaccine supply to 3 billion doses in 2022 Moderna has announced a set of additional investments to allow it to increase global supply of its COVID-19 vaccine. ‘We believe there will continue to be significant need for our vaccine into 2022 and 2023’, says the company.
The company also expects to increase 2021 supply to between 800 million and 1 billion doses.
Today’s announcement, alongside other news from fellow mRNA heavyweights Pfizer/BioNTech this month, illustrates how companies and governments are starting to plan for mass supplies of COVID-19 vaccines over the longer term.
Longer term plans start to come into focus